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Abstract
Atherogenesis is an inflammatory process with leukocytes
infiltrating the arterial intima. The lipoxygenase pathways
play a role in leukocyte recruitment through the generation
of two classes of arachidonic acid lipid mediators, the leu-
kotrienes and the lipoxins, and one class of omega-3 fatty
acid metabolites, the resolvins. There is evidence from ani-
mal studies and human genetic studies that the leukotrienes
and the enzymes necessary for their generation play a role
in atherosclerosis, and possibly even in the development of
the vulnerable plaque. Less is known about the effect of the
anti-inflammatory lipid mediators in atherosclerosis, the
lipoxins and the resolvins. Studies modulating the activity of
an enzyme necessary for the production of these lipid medi-
ators, 12/15-lipoxygenase, showed discrepant results in sev-
eral animal models. Also, human genetic studies have not
clearly dissected the effect of the enzyme on atherosclerosis.
However, stable forms of the lipoxins and the resolvins pro-
tect animals from inflammatory diseases. Whether blocking
the leukotrienes or applying anti-inflammatory lipoxins and
resolvins will be effective in attenuating human atheroscle-
rosis needs to be demonstrated in future studies. In this
review, the biosynthesis of these lipid mediators, their bio-
logical effects and the evidence for their possible role in
atherosclerosis are discussed with an emphasis on human
disease.
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Lipid mediators in inflammation
When growth factors and cytokines bind to their receptors,
they can activate several phospholipases which act on
membrane phospholipids to release arachidonic acid (1). The
released arachidonic acid forms a pool of precursors that are
metabolized to distinct bioactive lipid mediators by a minor
cytochrome P450 monooxygenase (CYP) pathway, and two
major pathways: the cyclooxygenase (COX) pathway and the
lipoxygenase pathway (2). The exact profile and balance of
bioactive end products derived from this arachidonic acid
pool depends on the type of cell and tissue, and is determined
by the environmental and physiological context. While lipid
mediators of the CYP pathway have vasoactive properties,
and some of the genes of this pathway have recently been
associated with coronary artery disease in genetic studies (3,
4), not much is known about their role in human atheroscle-
rosis (5). In contrast, there is broad evidence for involvement
of COX derived lipid mediators in the pathogenesis of
atherosclerosis, and especially atherothrombosis, which has
recently been summarized in two excellent reviews (6, 7).
The third family of lipid mediators derives from arachidonic
and from omega-3 fatty acids through oxygenation by lipoxy-
genases, and is the focus of this review.
The lipoxygenase pathways in inflammation
The lipoxygenase pathway results in lipid mediators with
opposing actions on inflammation. The pro-inflammatory
leukotrienes and the anti-inflammatory lipoxins, resolvins
and protectins show sequential evolvement during acute
inflammation (Figure 1). The pro-inflammatory leukotrienes
are secreted following the appearance of polymorphonuclear
neutrophils (PMN) in the acutely inflammed region, while
anti-inflammatory lipoxins and resolvins increase only dur-
ing the resolution of inflammation (8, 9). Three human
lipoxygenase activities have been described in the context of
leukotriene and lipoxin synthesis: the 5-lipoxygenase, the 12-
lipoxygenase and the 15-lipoxygenase activity. The naming
convention for these enzymes is determined by the position
of the carbon which is oxidised from the carboxy end of the
fatty acid. In general, the pro-inflammatory effect of the
products of the 5-lipoxygenase pathway is counteracted by
arachidonic acid metabolites generated by the 12- and 15-
lipoxygenase pathways (8, 9).
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Figure 1 Biosynthetic pathways and receptors for leukotrienes and lipoxins derived from the omega-6 fatty acid, arachidonic acid.
cPLA2, cytosolic phospholipase A2; FLAP, 5-lipoxygenase activating protein; ALOX5, 5-lipoxygenase; ALOX12/15, 12-lipoxygenase/15-
lipoxygenase; COX-2, cyclooxygenase-2; LTA4H, leukotriene A4 hydrolase; LTC4S, leukotriene C4 synthase; LTA4, leukotriene A4; LTB4,
leukotriene B4; LTC4 – E4, cysteinyl leukotriene C4 – cysteinyl leukotriene E4; 15-S-HETE, 15S-hydroxy-eicosatetraenoic acid; 15-R-
HETE, 15R-hydroxy-eicosatetraenoic acid; 15-oxo-ETE, 15-oxo-eicosatetraenoic acid; LXA4, lipoxin A4; 15-epi-LXA4, 15-epi-lipoxin A4
(aspirin-triggered lipoxin A4); BLT1 and BLT2, leukotriene B4 receptor 1 and 2; ALXR, lipoxin A4 receptor (FPRL1); AHR, aryl hydro-
carbon receptor; CysLT1 and CysLT2, cysteinyl leukotriene receptor 1 and 2; q, activation of receptor; –, blocking of receptor.
Biosynthesis of leukotrienes
The initial steps in leukotriene biosynthesis (Figure 1)
involve the oxygenation of arachidonic acid by 5-lipoxyge-
nase in the presence of 5-lipoxygenase activating protein
(FLAP). During these steps arachidonic acid is oxygenated
to LTA4. Then, this labile metabolite is converted by either
LTA4 hydrolase (LTA4H) to LTB4 or by LTC4 synthase
(LTC4S) to cysteinyl leukotrienes (10). Synthesis of cystei-
nyl leukotrienes proceeds with conjugation of LTA4 with
reduced glutathione by LTC4 synthase to form LTC4. This
active cysteinyl leukotriene is then exported from the cells
into the extracellular compartment through a specific ABC
transporter (11), where it is converted to cysteinyl leuko-
trienes LTD4 and LTE4 through sequential amino acid
hydrolysis.
There is evidence that the formation of leukotrienes, LTB4
and cysteinyl leukotrienes is mediated for some part through
transcellular mechanisms involving leukocytes and non-mye-
loid cells. While the expression of 5-lipoxygenase is restrict-
ed to myeloid cells, LTA4H and LTC4S are expressed in
several tissues and cell types including erythrocytes, plate-
lets, endothelial cells, eosinophils and mast cells (12–14).
Thus, it is thought that a considerable part of the intermediate
metabolite LTA4 is secreted from myeloid cells and con-
verted to LTB4 or cysteinyl leukotrienes by non-myeloid
cells (15, 16). The separation of the rate limiting enzymes in
different cell types may constitute an additional regulatory
mechanism to control the production of these important
mediators and contribute to the overall inflammatory
response (15, 16).
The synthesis of the leukotrienes is regulated by the
amount of arachidonic acid released from phospholipids
from the cell membrane by cytosolic phospholipase A2
(cPLA2), by the abundance of the enzymes involved in the
leukotriene synthesis pathway, and by the subcellular local-
ization of 5-lipoxygenase (17, 18). In resting cells, 5-lipoxy-
genase resides in the cytoplasm or the nucleoplasm, upon
activation it translocates to the nuclear membrane to interact
with FLAP. FLAP has no enzymatic activity, but improves
the interaction of 5-lipoxygenase with the substrate and
locates the 5-lipoxygenase to the nuclear membrane (19). 5-
Lipoxygenase maintains maximal efficiency when it is locat-
ed at the inner nuclear membrane, leading to maximal LTB4
synthesis (20). Phosphorylation of two serins was shown to
regulate the nuclear localization of 5-lipoxygenase, with
phosphorylation of Ser-523 inhibiting nuclear import (21)
and phosphorylation of Ser-271 inhibiting nuclear export
(22).
Biosynthesis of lipoxins
Lipoxins are increasingly recognized as key mediators in the
resolution of inflammation. They are synthesized by three
major pathways (Figure 1). The first pathway, initiated by 5-
lipoxygenase, was first described during platelet-leukocyte
interaction (23). Initially, LTA4 is released by activated leu-
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Figure 2 Biosynthetic pathways and receptors for protectins and resolvins derived from the omega-3 fatty acids eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA).
cPLA2, cytosolic phospholipase A2; ALOX15, 15-lipoxygenase; COX-2, cyclooxygenase-2; CYP450, cytochrome P-450 enzyme; ALOX5,
5-lipoxygenase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; 17-HDHA, 17-hydroxy-docosahexaenoic acid; 18R-HEPE, 18R-
hydroxy-eicosapentaenoic acid; PD1, protectin D1; RvD1, resolvin D1; RvE1, resolvin E1; ChemR23, chemerin receptor (CMKLR1);
BLT1, leukotriene B4 receptor 1.
kocytes and then made available for further metabolic pro-
cesses with neighboring cells (23). When platelets and leuko-
cytes aggregate, the human 12-lipoxygenase converts LTA4
to lipoxin A4 and B4. Through this interaction, platelets may
become the major source of lipoxins, given their high expres-
sion of 12-lipoxygenase, although they cannot produce
lipoxins on their own (23).
The second pathway is initiated by 15-lipoxygenase activ-
ity from ALOX15. The role of this 15-lipoxygenase pathway
is most clearly demonstrated in airway epithelial cells, such
as monocytes or eosinophils, which upregulate ALOX15
expression following stimulation with IL-4 and IL-13 (24,
25). These two cytokines are negative regulators of inflam-
mation, and are thought to play a role in the resolution of
inflammation (26). When the cells are stimulated by these
cytokines they generate 15S-hydroxy-eicosatetraenoic acid
(15-S-HETE). These compounds are rapidly converted to
lipoxins by the 5-lipoxygenase of monocytes and neutrophils
(27). These transformations can occur in humans following
secretion of 15-S-HETE via transcellular routes, or within
the cell of origin (23, 28). Recently, it was shown that
ALOX15B may also play a role in innate immunity since it
is expressed in human macrophages and is regulated by
hypoxia, which leads to increased 15-S-HETE production
(29). Importantly, 15-S-HETE itself can activate anti-inflam-
matory peroxisome proliferator-activated receptor-g
(PPARg) receptors (30, 31) and suppresses LTB4 induced
neutrophil chemotaxis (32). However, its primary anti-
inflammatory function may well be as a precursor for the
more potent lipoxins.
The third pathway for lipoxin production involves the anti-
inflammatory drug acetylsalicylic acid (aspirin), which is
known to suppress prostaglandin synthesis through covalent
acetylation of the COX-2 enzyme. However, acetylated
COX-2 is still enzymatically active and produces 15-R-
HETE instead of prostaglandins from arachidonic acid (33).
This metabolic intermediate is then converted through 5-
lipoxygenase activity to the 15-epi-lipoxins, also called aspi-
rin-triggered lipoxins (ATL). 15-Epi-lipoxins are more potent
and longer acting than their native 15S-containing lipoxin
forms because they are less rapidly metabolized (34, 35).
Biosynthesis of these 15-epi-lipoxins was shown to derive,
in part, from transcellular pathways between endothelial cells
and leukocytes (33), with the endothelial cells supplying
acetylated COX-2 enzyme in the presence of aspirin, and
leukocytes adding the 5-lipoxygenase activity (36). Indeed,
the formation of 15-epi-lipoxins has been detected in vivo in
an aspirin-dependent manner in several murine models of
inflammation (37), as well as in aspirin-treated healthy vol-
unteers (38, 39).
Biosynthesis of resolvins and protectins
In contrast to the lipoxins which derive from arachidonic
acids, the resolvins and protectins are produced from omega-
3 fatty acids (Figure 2) by sequential metabolism of CYP450
or acetylated COX-2 enzyme and lipoxygenases (40, 41).
The D-series of resolvins and protectins are derived from
omega-3 fatty acid docosahexaenoic acid (DHA), while the
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E-series are derived from eicosapentaenoic acid (EPA). Two
pathways each have been proposed for formation of the
resolvin series and for the protectins (Figure 2).
One of the pathways for the D-series involves 5- and 15-
lipoxygenase activity (42), with evidence that 15-lipoxyge-
nase activity from leukocytes or epithelial cells leads to
17S-hydroxy-DHA (42, 43). This has anti-inflammatory
effects and can be metabolized further by leukocyte 5-
lipoxygenase to the D-series of resolvins or by an epoxydase
to the protectins (40, 42, 44). In the second pathway, the
intermediate metabolite 17R-hydroxy-DHA is formed from
DHA by acetylated COX-2 (40) and further metabolized into
the D-series of resolvins and protectins (45). These transfor-
mations can occur through transcellular biosynthesis between
endothelial cells and leukocytes, or within a single cell type
in leukocytes.
Two pathways are also proposed for the generation of
resolvins of the E-series from EPA, which involve 5-lipoxy-
genase activity (Figure 2). Initially, acetylated COX-2 or
CYP450 transform EPA to the intermediate metabolite 18R-
hydroxy-eicosapentaenoic acid (18R-HEPE). This is then
metabolized by the leukocyte 5-lipoxygenase to form the E-
series of resolvins (40, 46, 47). Both pathways were shown
to be transcellular processes where the intermediate 18R-
HEPE was released from aspirin or cytokine treated endo-
thelial cells and subsequently metabolized to resolvin E1 by
leukocytes (46, 47).
Biosynthesis of other lipid mediators
The 5-lipoxygenase pathway is also involved in the produc-
tion of the five series of leukotrienes (LTB5) which derive
from EPA instead of arachidonic acid, and which results in
the four series of leukotrienes (LTB4). The five series of
leukotrienes have reduced pro-inflammatory and vasoactive
properties compared to the four series leukotrienes and are
thought to attenuate inflammation (48). Other lipoxygenase
derived metabolites have been described in macrophages like
15-oxo-eicosatetraenoic acid (15-oxo-ETE) and the macro-
phage mediators in resolving inflammation (maresins), which
derive from arachidonic acid and DHA, respectively. Not
much is known about the physiological or pharmacological
effects of these two classes, but there are indications that 15-
oxo-ETE inhibits endothelial cell proliferation (49), and that
maresins are potent mediators for resolving inflammation
(50). Another class of arachidonic acid derived lipid medi-
ators are the hepoxilins which were shown to inhibit lung
fibrosis and inflammation in mice, and to increase circulating
insulin concentrations in rats (51).
Inflammatory effects of leukotrienes
LTB4 is predominantly generated by neutrophils and mono-
cytes/macrophages, as well as by a subset of mast cells (52).
In vivo, LTB4 is a chemo attractant for leukocytes and
increases leukocyte rolling and adhesion to the endothelium,
followed by transendothelial migration. In fact, LTB4 is
among the most potent leukocyte stimuli (53) and also stim-
ulates secretion of superoxide anion and release of different
granule constituents from leukocytes (54, 55). These inflam-
matory effects are mediated through LTB4 specific G-pro-
tein-coupled receptors (Figure 1), the BLT1 and the BLT2
receptors (52).
The cysteinyl leukotrienes are produced by eosinophils,
basophils and mast cells, and have been identified as the
slow reacting substances of anaphylaxis (56). The cysteinyl
leukotrienes are the most potent bronchoconstrictive sub-
stances described (57). They result in plasma exudation in
all airway segments (58), stimulate mucus secretion in iso-
lated airways (59, 60), increase infiltration of eosinophils
into the airway mucosa of patients with asthma (61), and
may be involved in smooth muscle proliferation and remod-
elling in airways (62). Given their high potential as pro-
inflammatory and bronchoconstrictive mediators, cysteinyl
leukotriene over production during asthma can contribute to
formation and maintenance of airway inflammation and air-
flow obstruction (63). Two receptors belonging to the family
of G-protein-coupled receptors (CysLT1 and CysLT2) have
been identified which mediate the effects of the cysteinyl
leukotrienes (Figure 1). The CysLT1 receptor is stimulated
by all CysLTs, while the CysLT2 receptor is stimulated pri-
marily by LTC4 and LTD4 (63). Several drugs blocking the
CysLT1 receptor have been developed and are now used to
treat patients with asthma.
Anti-inflammatory effects of lipoxins and
resolvins
The 12- and 15-lipoxygenase derived lipoxins antagonize the
pro-inflammatory effects of leukotrienes, reduce neutrophil
chemotaxis and block neutrophil entry across the intestinal
epithelium (64). Lipoxin A4 and B4 both attenuate leuko-
triene C4 and B4 responses and reduce neutrophil adherence
to human umbilical vein endothelial cells (65), which likely
results from downregulation of P-selectin expression (66).
Application of lipoxins and stable lipoxin analogues in vivo
also antagonize VEGF induced endothelial cell proliferation
and angiogenesis (67), leukotriene C4 mediated vasocon-
striction in patients with asthma (68), and significantly inhib-
it both neutrophil infiltration and neutrophil-mediated
vascular injury in mice (69). Blocking of leukotriene C4 sig-
nalling was effected by competition of the lipoxins with the
leukotrienes for binding sites at the CystLT receptor.
Also, there is a direct anti-inflammatory effect of lipoxins
that is independent of leukotrienes and their cognate recep-
tors. Recently, the G-protein-coupled receptor FPRL1 was
shown to display specific and selective lipoxin A4 binding
(70). Upon stimulation with lipoxin A4, this receptor, now
termed lipoxin A4 receptor (ALXR), transmits signals which
result in the regulation of the p38 MAPK cascade and atten-
uation of tumor necrosis factor-a (TNF-a) induced nuclear
factor-kB (NF-kB) activation (71, 72). These two pathways
are implicated in chemotaxis and pro-inflammatory reactions,
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respectively. The second receptor involved in lipoxin signal-
ing is the aryl hydrocarbon receptor (AHR) which was
shown to signal lipoxin mediated SOCS-2 expression (73).
The SOCS proteins are thought to regulate cytokine triggered
signal transduction by docking to the intracellular domains
of the receptors, or by facilitating proteasome dependent deg-
radation of transcription factors (74). Thus, they play a major
role in resolution of inflammation (74).
The resolvins (Figure 2) have potent anti-inflammatory
effects, similar to the lipoxins. However, they appear to exert
their effects through a different set of receptors (75). Several
studies have shown that certain members of the resolvin fam-
ily suppress neutrophil infiltration and cytokine secretion in
animal models of inflammation (42, 76). Also, they have
been shown to be protective following brain injury after
experimental stroke (77), for insulin-resistance and hepatic
steatosis in obesity (78), airway inflammation (79, 80), and
they enhanced wound healing and suppressed colitis (75) in
mouse models of inflammatory diseases. Similar to lipoxins,
resolvins suppress inflammation by interfering directly with
the effect of leukotrienes on the receptor level and by sig-
nalling through designated receptors. Resolvin E1 seems to
suppress inflammation as a partial agonist for BLT1, damp-
ening the effect of leukotrienes, and by signalling through a
specific receptor, ChemR23, which was shown to transmit
anti-inflammatory signals (75, 81).
Protectin D1 was originally observed as the first anti-
inflammatory metabolite of the omega-3 fatty acid DHA
with anti-apoptotic and anti-inflammatory effects (82). Pro-
tectin D1 protects human retinal pigment epithelial cells from
oxidative stress and ganglion cells from cell death (82–84).
Also, it is neuroprotective in models of experimental stroke
by down regulating leukocyte infiltration following brain
ischemia reperfusion, and reduces infarct size (77). Overall,
protectin D1 promotes brain cell survival through the induc-
tion of antiapoptotic and neuroprotective gene-expression
programs (85).
Role of the 5-lipoxygenase pathway in
atherosclerosis
The initial indications for a role of 5-lipoxygenase in athero-
sclerosis came from mouse studies which identified a locus
on mouse chromosome 6 that confers almost total resistance
to atherogenesis (86). Examining the congenic region of the
locus for potential positional candidate genes revealed that
the 5-lipoxygnenase was centered under the linkage peak,
and subsequent generation of mice deficient in the 5-lipoxy-
genase showed the same atherosclerosis resistant phenotype
(87). Later, investigations in mice lacking the 5-lipoxygenase
could not corroborate this pro atherosclerotic effect, but
linked the 5-lipoxygenase pathway to hyperlipidemia
dependent inflammation of the arterial wall and to the path-
ogenesis of aortic aneurysms (88).
The enzymes necessary for leukotriene production are
expressed in human atherosclerotic lesions (89), and the
expression of these enzymes correlates with disease severity
(90). For example, 5-lipoxygenase, FLAP and the LTA4
hydrolase are localized in macrophages of human lesions and
the number of positive cells increases in advanced lesions
(89, 90). Also, there is evidence that 5-lipoxygenase and
LTA4 hydrolase expression are higher in patients with vul-
nerable plaques compared with patients with stable lesions,
and that this increase is associated with clinical events, such
as acute ischemic syndromes (90, 91). The mechanism lead-
ing to vulnerable plaques may include an increase in metal-
loproteinase expression and activity (MMP-2 and MMP-9)
mediated by 5-lipoxygenase activity (92). Indeed, 5-lipoxy-
genase dependent production of LTB4 and signaling through
the BLT1 receptor has recently been shown essential for
MMP-2 and MMP-9 activation of vascular smooth muscle
cells by 4-hydroxynonenal, a product of lipid peroxidation
(93). Similarly, LTB4 was shown to increase the intima/
media thickness and expression of MMP-2 and MMP-9 in
human arteries following balloon dilatation and stent implan-
tation (92).
Another indication for the involvement of leukotrienes in
atherosclerosis comes from the finding that the LTB4 recep-
tor is expressed on all human cell types involved in athero-
sclerosis (94), and that antagonists of the LTB4 receptor
reduce formation of lesions in mice (95). Treatment with
receptor antagonists resulted in fewer macrophages infiltrat-
ing the lesion. Similarly, mice deficient in the LTB4 receptor
BLT1 showed reduced lesions when fed an atherogenic diet
for up to eight weeks (96). However, longer treatment result-
ed in similar lesions in BLT1 deficient and litter mate control
mice. This may be due to the presence of BLT2 receptors on
macrophages from BLT1 deficient mice. Such macrophages
still react to a chemotactic gradient of LTB4 (96).
Further support for the involvement of 5-lipoxygenase in
atherosclerosis comes from genetic studies in humans. In the
first set of studies, the potentially functional SP1 repeat poly-
morphism in the human 5-lipoxygenase promoter showed an
association with the degree of intima-media thickness in the
common carotid artery (97), and with coronary artery disease
in the ADVANCE cohort (98). However, no association was
seen with myocardial infarction (99). In the second set of
studies, FLAP was identified as a susceptibility gene for
myocardial infarction and stroke following genome wide
screening performed in Icelandic individuals (100). Initially,
two different FLAP haplotypes were associated with almost
a two-fold increase in risk for myocardial infarction, and a
1.5-fold increase for stroke in different ethnicities (100, 101).
While the role of FLAP in atherosclerosis may be contro-
versial for some ethnicities, the B haplotype of FLAP was
associated with an increased risk of coronary artery disease
in four independent reports from European populations, sub-
stantiating the role of this gene in the pathogenesis of cor-
onary artery disease (98, 102–107). In addition, treatment of
carriers with this haplotype using a FLAP inhibitor led to a
modest reduction in LTB4 and myeloperoxidase production
in leukocytes ex vivo in a prospective placebo controlled trial
(108). This suggests that FLAP inhibition may reduce some
oxidative and inflammatory stress, and that such treatment
may be beneficial in patients with atherosclerosis. In con-
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trast, a recent meta-analysis that included 9760 samples
found that neither the A or B haplotype of FLAP are asso-
ciated with increased risk for stroke. However, two inde-
pendent polymorphisms that are part of these haplotypes
were shown to moderately increase the risk for stroke (109).
It should be emphasized that the mechanism of how haplo-
type B could alter LTB4 production and promote atheroscle-
rosis is currently unknown. A recent study found no
difference in LTB4 production in neutrophils from carriers
with different FLAP haplotypes (110).
Inhibition of 5-lipoxygenase and FLAP will not only lead
to reduced LTB4 synthesis, but will also reduce the levels of
the cysteinyl leukotrienes, which may also play a role in
atherosclerosis. Support for the role of the cysteinyl leuko-
trienes in atherosclerosis comes from animal model interven-
tion studies using specific CysLT1 receptor blockers. These
drugs have been developed and are now used in asthma
patients to interfere with the pro-inflammatory and broncho-
constrictive effect of the cysteinyl leukotrienes. When the
CysLT1 receptor blocker montelukast was given to mice
prone to atherosclerosis, the mice showed decreased athero-
sclerosis (111). Similarly, montelukast was effective in
reducing atherosclerosis in a rabbit model of restenosis,
where the extent of the reduction was as effective as ator-
vastatin treatment (112).
The role of the cysteinyl leukotriene pathway on athero-
sclerotic disease has also been investigated in human genetic
studies using a functional polymorphism in the promoter
region of the leukotriene C4 synthase gene (LTC4S). This
polymorphism was shown to increase leukotriene C4 syn-
thase activity and LTC4 production in eosinophils (113), and
was associated with aspirin intolerant asthma (114). Inves-
tigation of this polymorphism in the large prospective
Copenhagen City Heart Study revealed a protective effect of
the –444 CC-genotype for risk of ischemic cerebrovascular
disease, but not for coronary disease (115, 116). However,
the same C-allele was associated with increased coronary
calcification and carotid atherosclerosis in women enrolled
in the longitudinal Muscatine Study (117). These contradic-
tory results have been explained by the distinct effects of the
cysteinyl leukotrienes on several cell types involved in ath-
erosclerosis. It also emphasizes that the role of cysteinyl leu-
kotrienes in human atherosclerosis remains to be elucidated.
The fact that the enzymes necessary for the formation of the
cysteinyl leukotrienes and the CysLT receptors are expressed
in normal and diseased arteries (94) warrants further research
on the role of this class of lipid mediators in atherosclerosis.
Role of the 12- and 15-lipoxygenase pathways
in atherosclerosis
There is evidence for an anti-inflammatory effect of 15-
lipoxygenase through the generation of lipid mediators
involved in the resolution of inflammation (118). The oxi-
dation of arachidonic acid by human 15-lipoxygenases leads
preferentially to 15-HETE wfor review see (118)x. This can
either serve directly as an activator of the PPARg receptor
(30), or can be further metabolized to lipoxins (119).
Because the lipoxins were shown to inhibit chemotaxis,
adhesion and transmigration of neutrophils, and to antago-
nize the pro-inflammatory effects of leukotrienes (120), 15-
lipoxygenase is thought to play an anti-inflammatory role in
the pathology of chronic inflammatory diseases (121).
There is also evidence for a pro-atherosclerotic effect of
15-lipoxygenase through the formation of oxLDL and its role
in angiotensin II mediated mechanisms and vascular smooth
muscle cell proliferation (122–126). Hence, 15-lipoxyge-
nases seem to play a dual role, with an anti-inflammatory
effect through lipoxin and resolvin production, and a pro-
inflammatory and atherogenic effect through oxLDL for-
mation and participation in signaling pathways (118).
Animal models of atherosclerosis have not solved the
question of whether 15-lipoxygenase activity is pro- or anti-
atherogenic because different animal models have shown
contrasting results. Monocyte specific 15-lipoxygenase
expression in transgenic rabbits reduced atherosclerosis and
supported the anti-inflammatory role of 15-lipoxygenase
(127, 128). Similarly, an extensive mouse study that used
several overexpressing and knockout mouse lines showed an
atheroprotective effect of 15-lipoxygenase (129). However,
conditional macrophage-specific and general disruption of
the mouse homologue 12-lipoxygenase gene reduced ather-
osclerosis (130, 131), while overexpression of human 15-
lipoxygenase in vascular endothelium enhanced atherosclero-
sis in other mouse strains (132).
The discrepancies between the different animal models
have been explained by the different positional selectivity of
mammalian 12- and 15-lipoxygenase iso-enzymes which
oxidize arachidonic acid at carbon atoms 12 and 15, and
which have different expression patterns (118). Humans have
three 12-lipoxygenases and two 15-lipoxygenases which
show discrete expression patterns, substrate specificities, and
stereo-selective metabolism (118). However, only ALOX12
and two 15-lipoxygenases, ALOX15 and ALOX15B, seem
to be expressed in cells involved in atherosclerosis. Another
explanation for the discrepancies between the different ani-
mal models was recently proposed from results of a study in
mice lacking 5-lipoxygenase and 15-lipoxygenase activity,
either individually or combined (133). In these experiments,
shunting of substrate from the 15-lipoxygenase pathway to
the 5-lipoxygenase pathway was observed following inacti-
vation of the 15-lipoxygenase pathway. Such intra- and even
intercellular shunting of substrate seems to be common
(134), and may lead to ambiguous findings depending on the
genetic background, immune status of the animals, and on
the composition of the food used.
These different effects of 15-lipoxygenase on atheroscle-
rosis in different model systems preclude a prediction of the
role of 15-lipoxygenase in human atherosclerotic disease. To
answer this question, genetic studies have been performed in
humans to investigate the association of the human 15-
lipoxygenase with coronary artery disease and myocardial
infarction. Two rare functional polymorphisms have been
characterized in the 15-lipoxygenase gene which lead to
increased (c.–292C)T) (135) and reduced (T560M) (136)
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enzyme activity. While the activating c.–292C)T polymor-
phism showed a trend for an atheroprotective effect in a
small case control study of coronary artery disease, the inac-
tivating T560M polymorphism was associated with a signif-
icantly increased risk for coronary artery disease in the
ADVANCE study (136, 137). These results indicate that
ALOX15 may be anti-inflammatory and anti-atherogenic in
humans. However, corroboration of such an atheroprotective
effect of the 15-lipoxygenase gene was unsuccessful in a
recent large case control study, the MONIKA/KORA cohort
which investigated the effect of these polymorphisms on
myocardial infarction (138). In this study, the activating
c.–292C)T polymorphism showed no effect on the risk for
myocardial infarction, while the inactivating T560M poly-
morphism showed a trend for an association with myocardial
infarction, with a similar risk increase (OR 1.7) as reported
in the ADVANCE study (136). Thus far, all large study sam-
ples from Caucasians investigating the association of the
inactivating polymorphism (T560M) in 15-lipoxygenase
showed a similar risk increase. However, this was found not
to be significant in two of the studies because of the low
frequency of the T560M polymorphism (136, 138). Taken
together, the role of the 15-lipoxygenase enzyme in human
atherosclerosis has not yet been solved, although there is
currently more support for a neutral or atheroprotective role
for 15-lipoxygenase in human disease, than for promoting
atherosclerosis.
Conclusions and perspectives
The lipoxygenase pathways play a role in leukocyte recruit-
ment and activation, with the generation of leukotrienes,
lipoxins and resolvins. Although most of the information on
these mediators derives from animal models of acute inflam-
mation or asthma, there is evidence that they also play a role
in human chronic inflammatory diseases, such as rheumatoid
arthritis and atherosclerosis. The fact that the enzymes nec-
essary for the production of the pro-inflammatory leuko-
trienes are expressed in human atherosclerotic lesions, and
that the expression of these enzymes seems to correlate with
disease severity and features of vulnerable plaque, makes the
5-lipoxygenase pathway and the receptors for the generated
leukotrienes interesting targets for drug intervention in
human atherosclerosis. Such anti-leukotriene agents which
have been developed to treat patients with asthma are now
being investigated for their effectiveness in the cardiovas-
cular setting using intermediate cardiovascular endpoints. In
addition to these currently used 5-lipoxygenase inhibitors
and CysLT receptor blockers, there are novel drugs emerging
which block the BLT1 receptor or which inhibit several
metabolizing enzymes together; i.e., COX-2 and 5-lipoxy-
genase. Intervention studies with these drugs will further
show the role of the 5-lipoxygenase pathway in human ath-
erosclerosis, and may lead to a novel class of drugs to slow
the disease.
The role of 15-lipoxygenase in human atherosclerosis is
not yet clear, and human research is necessary to clarify this
role. To this end, large human genetic studies investigating
the association of the two rare functional polymorphisms
with different clinical end points may delineate the role of
the enzyme in human atherosclerotic disease. However, less
ambiguity exists about the effect of the lipid mediators pro-
duced by the 15-lipoxygenase pathway, the lipoxins and the
resolvins. These lipid mediators have anti-inflammatory and
pro-resolution properties. Also, the stable forms of these
mediators may have the potential to serve as a novel class
of anti-inflammatory drugs. However, the usefulness of these
drugs to decrease atherosclerosis will depend on the expres-
sion of the specific receptors for these lipid mediators on
cells present in the atherosclerotic plaque, and on their effect
on chemotaxis and activation of leukocytes. It will be essen-
tial to investigate whether increased monocyte recruitment
by some of these anti-inflammatory lipid mediators will be
protective, or accelerate atherosclerosis.
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